About Us

Cinclus Pharma AG

Board and management team

 

Peter Unge, MD, PhD

Chair of the Board, Chief Medical Officer and Co-Founder

Peter Unge has more than 25 years of experience from leading drug development at AstraZeneca HQ and Novartis HQ. He was assigned VP at Novartis and became the Head of Scientific Review Committee covering both the early and later stages of clinical drug development, in addition to his role as Head of the SOP Governance and Training Compliance Offices. Peter is also the inventor of modern treatment of gastric and duodenal ulcer disease which he optimized during his time at AstraZeneca. Peter is an MD with gastroenterology and internal medicine as specialist areas, has a PhD in Medicine and became Docent at Örebro University, Sweden.

 

Kjell Andersson, PhD

Board member, CEO and Co-Founder

Kjell Andersson has more than 30 years’ experience from drug development at AstraZeneca. He has industry experience covering drug discovery and development through to marketed products. He was preclinical project leader both for Losec and Nexium and had the same role in the development of linaprazan. Kjell holds a B.Sc. in Biology and Chemistry and a PhD in Pharmacology

 

Cinclus Pharma Holding AB

Board and management team

 

Wenche Rolfsen, PhD, Professor

Chair of the Board 

Wenche Rolfsen has more than 30 years in drug discovery and development from Pharmacia and Quintiles. Over the last 15 years, she has been on the Board of many life science companies, private, governmentally owned and publically listed in Norway, UK or Sweden. Wenche Rolfsen is currently active as Chairman of Index Pharmaceutical, Bioarctic AB and Sarsia Seed AS and member of the Board of Swedish Match and Recipharm. She holds a PhD in Pharmacology 

 

Lennart Hansson, PhD 

Board Director

Lennart Hansson has more than 20 years R&D and BD management experience from biotech and pharma companies such as KabiGen AB, Symbicom AB, AstraZeneca and Biovitrum and served as CEO for Arexis AB. Over the last ten years he has been engaged as a partner, Karolinska Development 2006-2008 and 2008-2016 head for the life science business of Industrifonden. Currently he is an independent consultant and acts in various advisory and board functions.  Lennart has been engaged in more than 30 companies as a board member or chairman and is currently active in the board of 6 companies. He holds a PhD in Genetics. 

 

Peter Unge, MD, PhD

Board Director and Chief Medical Officer

Peter Unge has more than 25 years of experience from leading drug development at AstraZeneca HQ and Novartis HQ. He was assigned VP at Novartis and became the Head of Scientific Review Committee covering both the early and later stages of clinical drug development, in addition to his role as Head of the SOP Governance and Training Compliance Offices. Peter is also the inventor of modern treatment of gastric and duodenal ulcer disease which he optimized during his time at AstraZeneca. Peter is an MD with gastroenterology and internal medicine as specialist areas, has a PhD in Medicine and became Docent at Örebro University, Sweden.

 

Anders Öhberg, M.Sc.

Board Director

Anders Öhberg has 10+ years’ experience from drug development and medical affairs within the pharmaceutical industry. He has held a broad spectrum of positions within clinical trials, pharmacovigilance, quality assurance and medical affairs at Pfizer, Ipsen and Novartis. He was recently Medical Lead for the Swedish ophthalmology portfolio at Novartis and Nordic Medical Advisor at Santhera within ophthalmology and muscular dystrophy. Anders is currently Nordic/Baltic Associate Director Medical Affairs for the Ophthalmology franchise at Shire. Anders holds a master’s degree in medical sciences and clinical drug development from Uppsala University. 

 

Torbjörn Koivisto

Board Director 

Torbjörn Koivisto has more than 10 years’ experience as a business lawyer from law firms Mannheimer Swartling, Lindahl and Bird & Bird. Since 2006 he is working for his own company IARU AB, advising clients within the life sciences industry on matters of commercial and corporate law. He is currently active as a member of the Board of Moberg Pharma AB (publ), Hemcheck Sweden AB (publ), Xspray Pharma AB (publ) and Kibacq AB. Torbjörn holds an LL.M. from Uppsala University. 

 

Kjell Andersson, PhD

CEO and Co-Founder

Kjell Andersson has more than 30 years’ experience from drug development at AstraZeneca. He has industry experience covering drug discovery and development through to marketed products. He was preclinical project leader both for Losec and Nexium and had the same role in the development of linaprazan. Kjell holds a B.Sc. in Biology and Chemistry and a PhD in Pharmacology